Purpose. This study was conducted to study the influence of protein structure on the immunogenicity in wild-type and immune tolerant mice of well-characterized degradation products of recombinant human interferon alpha2b (rhIFNa2b). Methods. RhIFNa2b was degraded by metal-catalyzed oxidation (M), cross-linking with glutaraldehyde (G), oxidation with hydrogen peroxide (H), and incubation in a boiling water bath (B). The products were characterized with UV absorption, circular dichroism and fluorescence spectroscopy, gel permeation chromatography, reverse-phase high-pressure liquid chromatography, sodium dodecyl sulfate polyacrylamide gel electrophoresis, Western blotting, and mass spectrometry. The immunogenicity of the products was evaluated in wild-type mice and in transgenic mice immune tolerant for hIFNa2. Serum antibodies were detected by enzyme-linked immunosorbent assay or surface plasmon resonance.
INTRODUCTION
Nearly all therapeutic proteins induce antibodies. In many cases the incidence and the clinical consequences are limited, but the development of a number of promising new biopharmaceuticals has been stopped because of immunogenicity problems. The development of antibodies in patients may be associated with life-threatening side effects and limits the clinical use of biopharmaceuticals for the treatment of chronic and serious diseases for which there is no alternative effective medical treatment (1) .
There are two immunological mechanisms by which these antibodies are induced. A classical, relatively fast immune reaction occurs after treatment with a therapeutic protein from nonhuman origin, e.g., streptokinase or asparaginase. Patients react to these foreign proteins as to vaccines. A second mechanism for the induction of antibodies is based on breaking B-cell tolerance, which in general takes many months. This may occur in patients who are treated with products that are homologs of human proteins. The exact mechanisms by which therapeutic proteins break tolerance is unknown, although impurities and aggregates are known to be important factors (2Y8). Impurities may act as danger signals initiating a response to self-antigens, and aggregates may present the self-antigens in a repetitive array form, which is supposed to activate B-cells without T-cell help (9Y11).
Although several predictive approaches have been advocated, clinical trials are still the only way to establish the immunogenicity of protein drugs. Immune tolerant transgenic mice are the most useful tool in studying the immunogenicity of therapeutic proteins. They have been used to evaluate whether sequence variations of existing therapeutic proteins as insulin induced new epitopes (12) and to study the breaking of tolerance by aggregates (4) .
We have extended these studies and have evaluated whether such models can also be used for more detailed studies of the relation between structure of the therapeutic proteins and the breaking of B-cell tolerance. We selected recombinant human interferon alpha2b (rhIFNa2b) as model protein. Transgenic immune tolerant animals carrying the human IFNa2 gene are available (4) . Moreover, this protein is used in the treatment of a variety of malignancies and viral diseases (13) and has a record of relatively high immunogenicity (14) . The induction of antibodies is associated with the loss of efficacy (14) . Marketed rhIFNa2 products contain either rhIFNa2a or rhIFNa2b, which differ in one amino acid that does not affect immunogenicity (15) . A review of the production and purification process has been published (5) . Lyophilization of rhIFNa2b formulations containing human serum albumin and improper storage conditions were shown to lead to the formation of aggregates (5, 16) . The level of anti-rhIFNa2 antibodies was related to the presence of aggregates (5, 15) .
We present here data on the relation between the structure of rhIFNa2b, modified by different chemical and physical treatments, and its immunogenicity in wild-type and transgenic immune tolerant mice.
MATERIALS AND METHODS

Degradation of rhIFNa a a2b
RhIFNa2b (a gift from AlfaWassermann, Italy) was degraded in four different ways. All samples were in 10 mM sodium phosphate buffer (PB), pH 7.2.
To oxidize the rhIFNa2b, it was treated with hydrogen peroxide (H 2 O 2 ), according to the European Pharmacopeia (17), by incubating rhIFNa2b (1 mg/mL) with 0.005% (v/v) H 2 O 2 at 37-C for 20 h. Oxidation was stopped by the addition of 12 mg methionine per milliliter and incubation at room temperature for 1 h.
The metal-catalyzed oxidation was achieved by incubating rhIFNa2b (300 mg/mL) with 4 mM ascorbic acid and 0.04 mM CuCl 2 for 3 h at room temperature according to Li et al. (18) . The reaction was stopped by adding 100 mM EDTA to a final concentration of 1 mM.
The rhIFNa2b was also cross-linked with glutaraldehyde according to Braun et al. (4) : incubation of rhIFNa2b (200 mg/mL) with 0.04% (v/v) glutaraldehyde at room temperature for 2 min, followed by 20 h incubation after adding sodium borohydride in a final concentration of 1.2 mM. RhIFNa2b was also modified by incubating 300 mg/mL in a boiling water bath for 10 min.
The oxidized and glutaraldehyde samples were dialyzed against 10 mM PB before use. All samples were stored at j20-C.
Protein Concentration
Protein concentrations were measured with a modified Lowry method (19) . Bovine serum albumin (BSA; SigmaAldrich, Zwijndrecht, The Netherlands) was used as a standard.
Characterization of rhIFNa a a2b
Unless stated otherwise, all dilutions were in 10 mM PB and all analyses were performed without prior filtration.
UV Spectroscopy
UV spectra (200Y450 nm) of the samples (200 mg/mL) were recorded on a Perkin-Elmer Lambda 2 UV/VIS spectrophotometer in quartz cuvettes with a path length of 1 cm. Phosphate buffer (10 mM) was used as a blank.
Circular Dichroism Spectroscopy
Circular dichroism (CD) spectra were recorded from 260 to 180 nm at 25-C in 0.5-mm quartz cuvettes with a dual-beam DSM 1000 CD spectrophotometer (On-Line Instrument Systems, Bogart, GA, USA). The subtractive double-grating monochromator was equipped with a fixed-disk, holographic gratings (2400 lines/mm, blaze wavelength 230 nm), and 1.24-mm slits. The protein concentration was 100 mg/mL. Each measurement was the average of at least ten repeated scans (step resolution 1 nm, 1 s each step) from which the corresponding buffer spectrum was subtracted. The CD signals were converted to delta molar extinction based on a mean residual weight of 117. The curves were smoothed with GraphPad Prism 4.02 (San Diego, CA, USA), by taking the weighted average of 9 points.
Fluorescence Spectroscopy
Fluorescence emission spectra (280Y450 nm) of 55 mg/mL samples were measured in 1-cm quartz cuvettes in a Fluorolog III fluorimeter at 25-C while stirring. Excitation was at 295 nm. Slits were set at 5 nm. Integration time per data point was 0.1 s and the average of ten scans was taken. The buffer signal was subtracted.
Dynamic Light Scattering
Samples (200 mg/mL) were analyzed with dynamic light scattering (DLS) to obtain an average diameter of the particles (Z ave ) and their polydispersity at an angle of 90-. A Malvern CGS-3 apparatus equipped with HeYNe (633 nm) JDS Uniphase laser, an optical fiber-based detector, and ALV/LSE-5003 correlator was used.
Gel Permeation Chromatography
Samples (100 mg/mL) were analyzed with a Superdex 200 10/300 GL column (Amersham, Roosendaal, The Netherlands) using a mobile phase of 50 mM PB and 200 mM sodium chloride, filtered through a 0.2-mm filter prior to use, at a flow rate of 0.50 mL/min by a Waters 2695 controller equipped with an autosampler. Chromatograms were recorded with a photodiode array detector (model 2996, Waters, Milford, MA, USA). The column was calibrated by analyzing protein standards obtained from Sigma-Aldrich with known molecular weights (i.e., thyroglobulin, BSA, ovalbumin, a-chymotrypsin, and myoglobin).
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
The gels consisted of a separating gel containing 15% (w/v) acrylamide and 0.1% SDS, and a stacking gel containing 5% (w/v) acrylamide and 0.1% SDS. Gels of 0.75-mm thickness were run under reducing (sample buffer containing 5% (v/v) b-mercaptoethanol) and nonreducing (sample buffer without b-mercaptoethanol) conditions at 200 V at room temperature. The electrophoresis buffer was 25 mM tris(hydroxymethyl)aminomethane, 192 mM glycine, and 0.1% (w/v) SDS. Gel electrophoresis was performed with a Biorad Protean III system (Biorad, Veenendaal, The Netherlands). Samples analyzed under reducing conditions were boiled for 5 min before application to the gel. A low-range molecular weight standard (Biorad) was included on the gel for determination of molecular weight.
Western Blotting
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels were blotted onto a nitrocellulose sheet with a Scie-Plas semidry blotter (Scie-Plas, UK). Blots were blocked overnight at 4-C with 1% (w/v) nonfat milk powder in 0.005% (w/v) Tween 20 in phosphate-buffered saline (PBS) with constant orbital shaking. After washing with 0.005% (w/v) Tween 20 in PBS and with water, the blots were incubated with polyclonal rabbit anti-rhIFNa2b serum in 0.1% (w/v) nonfat milk powder in 0.005% (w/v) Tween 20 in PBS for 1 h at room temperature with constant orbital shaking. Blots were washed with 0.005% (w/v) Tween 20 in PBS and with water. Blots were incubated with peroxidase labeled anti-rabbit IgG (Sigma-Aldrich) in 0.1% (w/v) nonfat milk powder in 0.005% (w/v) Tween 20 in PBS for 1 h at room temperature with constant orbital shaking. Blots were washed with 0.005% (w/v) Tween 20 in PBS and with water and incubated in a solution of 4-chloro-1-naphtol (SigmaAldrich) in methanol (15% (v/v)), water, and H 2 O 2 (0.015% (v/v)). After color development the blots were stored overnight in the dark in water to increase the intensity of the bands.
Reverse-Phase High-Pressure Liquid Chromatography
A ProSphere C18 (300Å ; 5 u) was used in combination with an All-Guard C18 guard column (Alltech, Breda, The Netherlands). The column was equilibrated with 45% (w/w) acetonitrile in 0.2% (v/w) trifluoroacetic acid (TFA) for at least 30 min. After application of the sample (50 mL, 100 mg/mL), a gradient of 45Y50% (w/w) acetonitrile in 0.2% (v/w) TFA in 25 min was applied to the column. The mobile phase was delivered to the column at a flow rate of 1 mL/min by a Waters 2695 controller equipped with an integrated autosampler. Chromatograms were recorded with a photodiode array detector (model 2996, Waters, Milford, MA, USA).
Mass Spectrometry
Mass spectrometric measurements were performed on an electrospray ionization-time of flight (ESI-ToF) (LCT) mass spectrometer (Micromass, Manchester, UK) to obtain the total mass of the protein. The instrument was equipped with a Z-nano-electrospray source (Micromass) operating in the positive ionization mode. Nanoflow electrospray needles were made from borosilicate glass capillaries (Kwik-Fil; World Precision Instruments, Sarasota, FL, USA) on a P-97 puller (Sutter instruments, Novato, CA, USA). The needles were coated with a thin gold layer using a Scancoat Six sputter coater (Edwards Laboratories, Milpitas, CA, USA). To remove sodium ions, samples were dialyzed first overnight against 50 mM ammonium acetate.
To analyze and identify the oxidation sites in the oxidized rhIFNa2b samples, matrix-assisted laser desorption ionization mass spectrometry (MALDI-ToF/ToF; AB 4700 Proteomics analyzer; Applied Biosystems, Framingham, MA, USA) was used. This instrument is equipped with a 200-Hz Nd:YAG laser operating at 355 nm. Experiments were performed in a reflectron positive ion mode using delayed extraction. Typically, 2250 shots per spectrum were acquired in the MS mode.
The oxidized samples and native rhIFNa2b were reduced with dithiothreitol (DTT) and treated with iodoacetamide to protect the cysteines. After iodoacetamide treatment the samples were dialyzed against 10 mM PB and digested with trypsin (Sigma-Aldrich) for 20 h at 37-C. The trypsin to protein ratio was 1 to 50 (w/w). The digested protein was mixed with 5 mg/mL a-cyano-4-hydroxycinnamic acid in 50% acetonitrile and 0.1% TFA and spotted on the MALDI plate. The obtained mass spectra were compared with theoretical peptide masses obtained after theoretical digestion of the protein and oxidation of the methionines using the Bproteomics tools^utility of the ExPASy web site (20) .
Immunogenicity
Animal Experiment
The animal experiment was approved by a Dutch Ethical Committee. Wild-type (FVB/N) mice were obtained from Charles River Laboratories (Wilmington, MA, USA). Food (Hope Farms, Woerden, The Netherlands) and water (acidified) were available ad libitum.
To test the immunogenicity of the samples, wild-type or transgenic mice (five per group) were injected intraperitoneally (i.p.) with 10 mg protein on days 0Y4, 7Y11, and 14Y18. Blood was taken from the vena saphena on days 0, 7, and 14 before injection, and on day 21. The blood samples were incubated on ice for 2 h. Sera were collected after centrifugation and stored at j20-C.
To make sure that the immune tolerance of the transgenic mice was specific for hIFNa2, five wild-type and five transgenic mice were immunized with 10 mg ovalbumin using the same injection protocol as described above. The presence of antiovalbumin antibodies in the serum was determined as described below.
Serum Analysis by ELISA
Sera were analyzed by enzyme-linked immunosorbent assay (ELISA) for the presence of antibodies against native rhIFNa2b and against the corresponding degraded sample, or against ovalbumin. Microlon 96-well plates (Greiner, Alphen aan den Rijn, The Netherlands) were incubated with 100 mL/well of a solution (2 mg/mL) of native rhIFNa2b, degraded rhIFNa2b, or ovalbumin for 1 h at room temperature with constant orbital shaking. Then the wells were drained and washed four times with 300 mL wash buffer (0.1% (w/v) Tween 20 in PBS. After washing the wells were carefully tapped dry on a tissue. Wells were blocked by incubating with 200 mL 2% (w/v) BSA in PBS for 1 h at room temperature with constant orbital shaking. The plates were drained and washed four times with 300 mL wash buffer. After the last wash, wells were carefully tapped dry on a tissue. Serum dilutions (1:100) were added to the wells and the plates were incubated for 1 h at room temperature with constant orbital shaking. The plates were washed four times with 300 mL wash buffer. After the last wash, wells were carefully tapped dry on a tissue. Peroxidase labeled anti-mouse IgG (SigmaAldrich) was added to the wells and the plates were incubated for 1 h at room temperature with constant orbital shaking. Plates were drained and washed four times with 300 mL wash buffer and twice with 300 mL PBS. After the last wash, wells were carefully tapped dry on a tissue. 2,2 0 -Azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) substrate (Roche, Almere, The Netherlands) was added and absorbance was recorded after 30 min of incubation, on a Novapath microplate reader (Biorad) at a wavelength of 415 nm and a reference wavelength of 490 nm. During all incubation steps the plates were covered. Sera were arbitrarily defined positive when the absorbance value of the 1:100 dilution of the sera minus the background was three times higher than the average absorbance value of the pretreatment sera minus the background.
To determine the antibody titer of the positive sera, the sera were added to the plates, coated with native rhIFNa2b or ovalbumin, in serial dilutions (starting from 1:10). The other steps of the ELISA procedure were as described above and the absorbance values were plotted against log dilution. Curves were fitted with a sigmoidal curve (GraphPad Prism version 4.02 for Windows, GraphPad Software; GraphPad, San Diego, CA, USA). The dilution needed to obtain 50% of the maximum absorbance was taken as the titer of the serum.
Serum Analysis by Surface Plasmon Resonance
Sera of the mice treated with boiled rhIFNa2b were analyzed via surface plasmon resonance (SPR) with a Biacore (Biacore, Uppsala, Sweden). Native and boiled rhIFNa2b were coupled via an amine coupling to two different flow cells of a CM5 sensor chip (Biacore, Sweden). The flow cells were washed with HBSYEP buffer [10 mM HEPES, pH 7.4, 0.15 M sodium chloride, 3 mM EDTA, 0.005% (w/v) Tween 20] . After the coupling, 10 mL serum (diluted ten times with HBSYEP buffer) of the wild-type mice (pooled per time point) or 10 mL serum (diluted 10-fold with HBSYEP buffer) of the transgenic mice (pooled per time point) was injected on the two different flow cells of the CM5 sensor chip. After the injection the amount of bound material was determined by measuring the increase in relative refractive index units. Complete dissociation of the sera from the sensor chips was obtained by washing the flow cells with a 1.5 M glycine solution.
RESULTS
Characterization of Degraded rhIFNa a a2b
All samples were optically clear and colorless, without visible aggregation or precipitation. Only after repeated freeze-thawing did boiled rhIFNa2b show visible precipitation. 
UV Spectroscopy
The UV spectra of proteins can give valuable information about the presence of aggregates in the solution. The metal-catalyzed oxidized and boiled rhIFNa2b preparations showed significant optical densities at 350 nm (Table I) and above, which indicates the presence of aggregates (21) . In boiled rhIFNa2b, metal-catalyzed oxidized rhIFNa2b, and glutaraldehyde-treated rhIFNa2b, a decrease in A 280 /A 260 ratio as compared to native rhIFNa2b was observed, which also indicated the presence of aggregates (21). The UV spectrum of H 2 O 2 -oxidized rhIFNa2b almost overlapped with native rhIFNa2b.
CD Spectroscopy
Far-UV CD spectroscopy was used to determine the secondary structure of rhIFNa2b, which contains 5 a-helices (data not shown). Native rhIFNa2b gave a far-UV CD spectrum typical for an a-helical protein. Metal-catalyzed oxidized rhIFNa2b showed a small reduction of the intensity of the entire spectrum (but not the shape), indicating a small decrease in a-helical content (Table I ). Glutaraldehydetreated and H 2 O 2 -oxidized rhIFNa2b showed similar far-UV CD spectra as compared to native rhIFNa2b. A far-UV CD spectrum of boiled rhIFNa2b could not be obtained due to the presence of precipitate in the solution.
Fluorescence Spectroscopy
Fluorescence spectroscopy, when performed with an excitation wavelength of 295 nm, gives information about the environment of the two tryptophans in rhIFNa2b at positions 76 and 140. In addition, the scattering of the light (signal of 295 nm) provides information on the presence of particles or aggregates in the solution.
Native rhIFNa2b showed an emission maximum at 337 nm and little scattering ( Table I ). The emission spectrum of metal-catalyzed oxidized rhIFNa2b was slightly redshifted, indicating a more hydrophilic environment of at least one of the tryptophans. The substantial increase in scatter intensity indicates the presence of aggregates. Glutaraldehydetreated rhIFNa2b showed also a slightly red-shifted maximum and an increased scatter peak, but less than metal-catalyzed oxidized rhIFNa2b. The emission spectrum of H 2 O 2 -oxidized rhIFNa2b had the same characteristics as that of native rhIFNa2b. The emission spectrum of boiled rhIFNa2b showed a large red shift, indicating that the environment of the tryptophans had become more hydrophilic. The protein was, however, not completely unfolded, because in 6 M guanidine chloride the emission maximum was at 356 nm (data not shown). The high intensity of the scatter peak of boiled rhIFNa2b was about the same as that of metal-catalyzed oxidized rhIFNa2b, pointing to extensive aggregation.
Dynamic Light Scattering
Only the metal-catalyzed oxidized and boiled rhIFNa2b samples scattered enough light to analyze the particle size by DLS. In the metal-catalyzed oxidized solution, the average diameter of the particles was ca. 0.7 mm, with a high polydispersity index (0.835), indicating the presence of aggregates heterogeneous in size. Boiled rhIFNa2b showed large (ca. 1Y3 mm) heterodisperse aggregates. Gel permeation chromatography (GPC) was used to analyze the samples for the presence of soluble aggregates ( Fig. 1 and Table II) . Native rhIFNa2b showed a peak of monomeric protein and a small dimer peak. Metal-catalyzed oxidized rhIFNa2b contained clearly less monomer than native rhIFNa2b, whereas dimers and some trimers had been formed. Also, a small, broad peak of larger aggregates was present in this sample. Glutaraldehyde-treated rhIFNa2b showed a huge decrease in monomer content, with a concomitant increase in di-, tri-, and tetramer content and some bigger oligomers. H 2 O 2 -oxidized rhIFNa2b showed a profile similar to that of native rhIFNa2b. Boiled rhIFNa2b did not show any peaks on GPC (data not shown), indicating that practically all protein molecules had formed insoluble aggregates.
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis
Formation of covalent aggregates was determined by comparing SDS-PAGE gels run under nonreducing and reducing conditions (Fig. 2a and b, respectively) . Native and H 2 O 2 -oxidized rhIFNa2b showed a monomer band and a small dimer band under nonreducing conditions. The dimer band was nearly absent under reducing conditions, indicating that the dimer formation was primarily mediated by disulfide bonds. Also, the multimeric bands of metal-catalyzed oxidized rhIFNa2b seen under nonreducing conditions were substantially less intense under reducing conditions, pointing to disufilde bonds forming the multimers. Both gels showed similarly intense bands of aggregated protein for glutaraldehyde-treated rhIFNa2b. These aggregates are apparently covalently linked via (nonreducible) glutaraldehyde cross-links. The nonreduced sample of boiled rhIFNa2b contained dimers and larger multimers formed through disulfide bridges, as they were almost absent after reduction of the samples.
Western Blotting
The reactivity of the individual bands on SDS-PAGE (nonreducing conditions) with polyclonal anti-rhIFNa2b serum was tested by Western blotting (Fig. 2c) . As expected, the monomer of native rhIFNa2b reacted with the polyclonal antiserum. This was also true for the single band of H 2 O 2 -oxidized rhIFNa2b. Aggregates that were present in metalcatalyzed oxidized rhIFNa2b and glutaraldehyde-treated rhIFNa2b reacted with the antiserum as well. The dimers and larger aggregates in boiled rhIFNa2b did not react with the polyclonal antiserum. Possibly the antiserum did not recognize the aggregates, or the amount of aggregates transferred onto the nitrocellulose sheet was too low to be detected by this method.
The monomer of glutaraldehyde-treated rhIFNa2b did not react with the antiserum. Apparently the chemical treatment had not only cross-linked the protein molecules, but also destroyed the immunodominant epitopes in the remaining monomer.
Reverse-Phase High-Pressure Liquid Chromatography
Only native and H 2 O 2 -oxidized rhIFNa2b showed peaks in the reverse-phase high-pressure liquid chromatography chromatogram (RP-HPLC) (data not shown). Metal-catalyzed oxidized, glutaraldehyde-treated, and boiled rhIFNa2b did not show any peaks, probably because the aggregated rhIFNa2b was captured by the guard column and the amount of nonaggregated rhIFNa2b was too low to be detected with this method. However, GPC showed that metal-catalyzed oxidized rhIFNa2b contained 43% of monomeric rhIFNa2b (Table II) . Possible explanations for the apparent discrepancy between GPC and RP-HPLC are: (1) the solubility of metal-catalyzed oxidized rhIFNa2b in the mobile phases used in RP-HPLC was lower than that of native rhIFNa2b; (2) the aqueous GPC solvent was capable of breaking apart noncovalent aggregates more easily than the organic RP-HPLC solvents; (3) a smaller amount of protein was applied on RP-HPLC than on GPC; (4) adsorption to the guard column present in RP-HPLC; or (5) a combination of the above possibilities.
Compared with native rhIFNa2b, H 2 O 2 -oxidized rhIFNa2b showed an extra peak with a shorter retention time, representing oxidized rhIFNa2b (5). Based on the peak areas, about 60% of the protein was oxidized.
Mass Spectrometry
In the electrospray mass spectrometer the protein becomes multiply charged, resulting in different m/z peaks in the mass spectrum (22) . From this so-called charge envelope, the mass of the sample can be calculated. The base peak of native rhIFNa2b had a mass of 19,266 Da (corresponding to the theoretical value of 19,269 Da (23)). The base peaks of both oxidized rhIFNa2b preparations corresponded to a mass of 19,282 Da. The increase of 16 mass units confirms the addition of 1 oxygen atom, indicating that oxidation had occurred. The peak corresponding to nonoxidized rhIFNa2b was also visible, indicating that not all molecules were oxidized. No peaks in the mass spectrum of glutaraldehydetreated rhIFNa2b could be obtained with this method; the sample was too heterogeneous in mass. Boiled rhIFNa2b had the same calculated mass as native rhIFNa2b. However, the charge envelope of the boiled sample contained more peaks and the average m/z ratio was shifted to lower m/z values, indicating that the boiled protein was unfolded (22) . Aggregates were not detected with this method. Table III shows the ratios of the peak intensities of peptides (obtained by tryptic digestion, see Materials and Methods) containing oxidized methionines over those of the corresponding nonoxidized peptides, as obtained with MALDI-ToF/ToF analysis. In native rhIFNa2b some oxidized peptides were detected. Methionines 17, 22, and 149 were shown to be oxidized in some of the protein molecules. In the oxidized samples, both metal-catalyzed oxidized as well as H 2 O 2 -oxidized, the fraction of molecules containing these methionines oxidized had increased substantially compared to native rhIFNa2b, as can be clearly seen from the higher peak ratios of oxidized/nonoxidized peptides (see a Only peptides containing both methionines were detected. These peptides were detected with 1 (17 or 22) or 2 (17 and 22) methionines oxidized. It was not possible to distinguish between the two methionines. b Only peaks corresponding to peptides containing the nonoxidized methioine were detected; no peaks corresponding to peptides containing the oxidized methionine were detected. c ND = no peaks of peptides containing this methionine were detected, neither oxidized, nor nonoxidized. Table III) . Peaks corresponding to peptides containing methionine 60, oxidized or nonoxidized, could not be detected for both oxidized samples. In addition, for metalcatalyzed oxidized rhIFNa2b no peaks corresponding to peptides containing methionine 112 could be detected. The mass spectra showed no evidence of oxidized amino acid residues other than the methionines. With MALDI-ToF/ToF of the peptide digests, more oxidation sites were found than with ESI-ToF of the intact polypeptide chain. Probably the peak intensity of oxidation products with more than one oxidation site was too low to be resolved by ESI-ToF.
Summary
The main characteristics of the degraded samples, including the estimated amount of aggregated species, are summarized in Table II .
Immunogenicity
Different immunization protocols (route of administration, dose, dosing schedule) were tested beforehand to optimize our animal model. We aimed for maximum and reproducible antibody levels for native rhIFNa2b in the wildtype mice. No matter which protocol was used, the transgenic mice never formed detectable antibodies against the native protein. This illustrates that they are immune tolerant for the native rhIFNa2b, indeed. These studies led to the immunization scheme mentioned in Materials and Methods.
To ensure that the immune tolerance of the transgenic mice is specific for hIFNa2 and not due to a general immune suppression mechanism, we compared the antibody response against ovalbumin in the wild-type and the transgenic mice. Ovalbumin is foreign to both the wild-type and the transgenic mice, and should therefore elicit similar antibody responses. Figure 3 shows that the anti-ovalbumin IgG titers of the wildtype and the transgenic mice are comparable indeed, illustrating that the immune system of the transgenic mice is fully functional.
The anti-rhIFNa2b IgG titers of the wild-type mice immunized with native and degraded rhIFNa2b are shown in Fig. 4a . Metal-catalyzed oxidized and H 2 O 2 -oxidized rhIFNa2b induced antibodies to native rhIFNa2b protein in the wild-type mice.
Only one of the wild-type mice treated with the boiled product produced antibodies to native rhIFNa2b, whereas glutaraldehyde-treated rhIFNa2b did not induce antibodies to native rhIFNa2b at all.
However, both the oxidized and glutaraldehyde-treated rhIFNa2b preparations did induce antibodies in the wild-type mice to the respective modified material (Fig. 4b) .
We failed to find an antibody response to native rhIFNa2b in the mice treated with boiled rhIFNa2b. To exclude the possibility that this lack of response was due to the inability to coat ELISA plates with boiled protein, we also analyzed the sera with SPR. With this technology, we picked up a weak antigenYantibody reaction, although it proved more difficult to immobilize boiled than native rhIFNa2b to the SPR chip. The boiled sample may have contained some native rhIFNa2b, which was more efficiently coupled to the chip than boiled rhIFNa2b. Therefore, we could not conclude from these results whether the antibodies were anti-rhIFNa2b or antiboiled rhIFNa2b. Figure 5 shows the antibody response of the immune tolerant transgenic mice treated with the different rhIFNa2bs. Only metal-catalyzed oxidized rhIFNa2b was able to break the immune tolerance in the transgenic mice. The other degraded samples did not induce an antibody response: neither to native rhIFNa2b (Fig. 5) nor to the corresponding samples (data not shown). Also, SPR failed to show antibodies against native or boiled rhIFNa2b in the sera of transgenic mice treated with boiled rhIFNa2b.
DISCUSSION
Aggregates in therapeutic protein formulations are known to be important factors in inducing an antibody response (4Y8). The immunological mechanism of this antibody induction is not completely understood. Aggregation may lead to conformational changes and the presentation of new epitopes. Aggregation may also lead to the type of multimeric epitope presentation that can break immune tolerance. Somehow, the B-cell receptor is capable of responding without T-cell help to epitope patterns meeting certain criteria, such as spacing of 5Y10 nm between at least ten repeating epitopes (10,24Y26).
For wild-type mice, rhIFNa2b is a foreign protein and it induces a classical immune response. All samples induced antibodies, although the level of antibodies induced by boiled rhIFNa2b was very low and antibodies were formed only in one mouse. The antibodies induced after immunization with glutaraldehyde-treated rhIFNa2b did not cross-react with native rhIFNa2b. This modified protein had apparently obtained new epitopes, due to the cross-linking, which are not present in native rhIFNa2b, as confirmed by Western blotting (Fig. 2c) . However, the aggregates present in glutaraldehyde-treated rhIFNa2b still contained native epitopes, but the level might be too low to elicit an immune response.
The observed poor immunogenicity of boiled rhIFNa2b was not expected but may be related to the size of the aggregates. The number of epitopes exposed to the immune system is inversely related to the size of the particles. Also, the large size of the aggregates may slow down the clearance from the peritoneal cavity or impair the uptake by phagocytic cells. It was previously shown by Phillips et al. (27) that liposomes (average size 130 nm) greatly decreased the clearance of encapsulated drugs out of the peritoneal cavity as compared to the free drug. The same authors also showed that the clearance was even more retarded when the liposomes were aggregated via avidin/biotin. The size of boiled rhIFNa2b could be well in the range of the aggregated liposomes.
In the transgenic mice immune tolerant for hIFNa2, antibodies to this protein can be induced either by breaking tolerance or via the classical immune response. Metalcatalyzed oxidized rhIFNa2b was the only preparation capable of inducing antibodies in the transgenic mice. It is unlikely that oxidation per se accounts for this immunogenicity, because H 2 O 2 -oxidized rhIFNa2b lacked this effect whereas both products showed the same oxidation sites. It is more likely that the aggregate formation accompanying the metal-catalyzed oxidation of rhIFNa2b was responsible for breaking the tolerance. The mechanism by which metalcatalyzed oxidation induces aggregation of rhIFNa2b is unknown, but aggregation has also been reported for metalcatalyzed oxidation of relaxin (18) . It should also be noted that H 2 O 2 -oxidized rhIFNa2b and native rhIFNa2b contain dimers, and apparently multimeric aggregation is needed to break tolerance.
Glutaraldehyde-treated rhIFNa2b contained aggregates that were not able to break tolerance in the transgenic mice. Antibody response in the wild-type mice showed this sample to contain new epitopes for which the transgenics lack tolerance. Nevertheless, the transgenic mice did not respond. A reason for this could be that T-cells recognized native linear epitopes, still present in the modified protein, for which the transgenic mice are immune tolerant. So the Tcells will not activate the B-cells into antibody production. In contrast with our results, Braun et al. (4) showed breaking of immune tolerance with glutaraldehyde induced aggregates. Reasons for this discrepancy could be differences in modification conditions, immunization protocol, and/or route of administration.
Altogether, our data indicate that the dogma ''aggregation leads to immunogenicity of therapeutic proteinsŝ hould be taken with caution. The three different aggregated samples (obtained by metal-catalyzed oxidation, by glutaraldehyde treatment, and by boiling), which differ both in size distribution and in protein structure, vary widely in immunogenicity: whereas aggregates obtained by metal-catalyzed oxidation are able to break the immune tolerance, those obtained by glutaraldehyde treatment and boiling are not. If optimally spaced (5Y10 nm) repetitive (more than 10) native (or native like) epitopes are the predominant mechanism by which aggregates would break immune tolerance (10,24Y26), only the metal-catalyzed oxidation product apparently fulfills these criteria. Also, the large aggregates detected by DLS and/or the larger aggregates detected by GPC, rather than the smaller oligomers observed by GPC, are most likely to be responsible for the increased immunogenicity of metalcatalyzed oxidized rhIFNa2b. Besides the number and the orientation of epitopes, however, the structure of the protein molecules that form the aggregates may be crucial. Both boiled rhIFNa2b (loss of native conformation) and glutaraldehyde-treated rhIFNa2b (major chemical modifications) may not sufficiently resemble native rhIFNa2b to break the immune tolerance. Thus, aggregates composed of native-like protein molecules may be more likely to break tolerance than aggregates consisting of denatured proteins. This would imply that preventing the formation of native-like aggregates should be a major task for protein formulation scientists in their search for nonimmunogenic therapeutic protein formulations.
CONCLUSIONS
In this study, we tried to correlate structure with immunogenicity and ability to break immune tolerance. We found that large aggregates of denatured protein are not necessarily more immunogenic than smaller aggregates composed of more Bnative-like^protein. It seems that both the structure of the constituent proteins and/or the size of the aggregates determine immunogenicity. We also found that oxidation in itself does not enhance immunogenicity. Moreover, we have shown that screening the immunogenicity of protein drugs should include assays for antibodies to the modifications present in the product.
Although the aggregates produced in this study may not fully represent the degradation products typically formed during production, storage, or handling of rhIFNa2b for-mulations, with the present study we gained more insight into which structural changes affect the immunogenicity of rhIFNa2b. Clearly, more research is needed to clarify the relation between structure and immunogenicity of rhIFNa2b in particular and therapeutic proteins in general, to assess the minimum amount of modified proteins inducing antibody formation and to evaluate the predictive value of immune tolerant transgenic mouse models for the immunogenicity of therapeutic proteins in patients.
